PRI-VENT FSGS: Preemptive Rituximab to Prevent Recurrent Focal Segmental Glomerulosclerosis Post-Transplant

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

July 1, 2019

Primary Completion Date

February 7, 2025

Study Completion Date

February 7, 2025

Conditions
Focal Segmental Glomerulosclerosis
Interventions
DRUG

Rituximab

Rituximab 375mg/m2 intravenous on day 0 or -1 prior to kidney transplant

PROCEDURE

Plasmapheresis

1.5 volume exchange plasmapheresis with fresh frozen plasma replacement

Trial Locations (12)

19104

Children's Hospital of Philadelphia, Philadelphia

27708

Duke University, Durham

35487

University of Alabama, Tuscaloosa

45221

University of Cincinnati, Cincinnati

45229

Cincinnati Children's Hospital, Cincinnati

52242

University of Iowa, Iowa City

55455

University of Minnesota, Minneapolis

55905

Mayo Clinic, Rochester

60611

Lurie Children's Hospital, Chicago

80045

Children's Hospital of Colorado, Aurora

95616

University of California at Davis, Davis

98105

Seattle Children's Hospital, Seattle

All Listed Sponsors
collaborator

United States Department of Defense

FED

lead

University of Minnesota

OTHER

NCT03763643 - PRI-VENT FSGS: Preemptive Rituximab to Prevent Recurrent Focal Segmental Glomerulosclerosis Post-Transplant | Biotech Hunter | Biotech Hunter